Table 1 Demographics and characteristics of patients with colorectal cancer receiving chemotherapy.

From: Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

 

Oxaliplatin (+) n = 78

Oxaliplatin (−) n = 20

P-value

Age (years)§

66 (37–83)

69.5 (33–87)

0.498

Sex ratio(M:F)

43: 35

14: 6

0.311#

Chemotherapy

CAPOX + BV

61

  

CAPOX

12

  

SOX

5

  

XELIRI + BV

 

6

 

SIRB

 

6

 

Capecitabine + BV

 

8

 

Puncture site

Median cubital vein: Median vein of forearm

39: 39

9: 11

0.804#

Vessel diameter*(cm)

3.6 (1.58)

3.3 (1.21)

0.516

  1. §Median (interquartile range). *Mean (SD). Unpaired Student’s t-test and #Fisher’s exact test.
  2. CAPOX: oxaliplatin and capecitabine; BV: bevacizumab; SOX: oxaliplatin and tegafur, gimeracil, oteracil potassium; XELIRI: irinotecan and capecitabine; SIRB: irinotecan and tegafur, gimeracil, oteracil potassium.
Back to article page